| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hiroshi Fukui | |
| P2860 | cites work | Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients | Q21091184 |
| Role of alcohol metabolism in non-alcoholic steatohepatitis | Q21142633 | ||
| The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate | Q24314242 | ||
| Identification of membrane-type receptor for bile acids (M-BAR) | Q24316461 | ||
| Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice | Q36961744 | ||
| Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium | Q37037647 | ||
| Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study | Q37072188 | ||
| Bacterial infections, sepsis, and multiorgan failure in cirrhosis | Q37091921 | ||
| Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. | Q37277544 | ||
| CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis | Q37384997 | ||
| High-fat diet determines the composition of the murine gut microbiome independently of obesity | Q37404989 | ||
| Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet | Q37411862 | ||
| Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. | Q37962297 | ||
| Immuno-microbiota cross and talk: the new paradigm of metabolic diseases | Q37977629 | ||
| Perspective: TGR5 (Gpbar-1) in liver physiology and disease | Q38004227 | ||
| Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. | Q38057416 | ||
| The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension | Q38074434 | ||
| Gut microbiota and non-alcoholic fatty liver disease: new insights | Q38085700 | ||
| Ethanol metabolism and its effects on the intestinal epithelial barrier | Q38118340 | ||
| Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature | Q38123531 | ||
| Interactions between the intestinal microbiome and liver diseases | Q38179779 | ||
| Gastrointestinal dysfunction in liver cirrhosis | Q38263849 | ||
| Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis | Q38308819 | ||
| Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. | Q38339644 | ||
| Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of Yersinia pseudotuberculosis | Q39890226 | ||
| Pseudomonas aeruginosa potentiates the lethal effect of intestinal ischemia-reperfusion injury: the role of in vivo virulence activation | Q39986933 | ||
| Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury | Q40489743 | ||
| Diversity of the human intestinal microbial flora | Q24544241 | ||
| Enteric dysbiosis associated with a mouse model of alcoholic liver disease | Q24594915 | ||
| Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa | Q24622141 | ||
| Metagenomic analysis of the human distal gut microbiome | Q24633486 | ||
| A core gut microbiome in obese and lean twins | Q24649648 | ||
| Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease | Q24734938 | ||
| Pathological bacterial translocation in liver cirrhosis | Q26824138 | ||
| Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia | Q26826919 | ||
| The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease | Q26852498 | ||
| Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases | Q26863752 | ||
| Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives | Q26864127 | ||
| Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis | Q26991664 | ||
| FXR signaling in the enterohepatic system | Q27014753 | ||
| Alcoholic liver disease: the gut microbiome and liver cross talk | Q27025627 | ||
| Alcoholic liver disease: pathogenesis and new therapeutic targets | Q27690220 | ||
| An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
| The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors | Q27860900 | ||
| Inflammation and metabolic disorders | Q27860923 | ||
| Microbial ecology: human gut microbes associated with obesity | Q27861004 | ||
| Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases | Q28131810 | ||
| Endogenous bile acids are ligands for the nuclear receptor FXR/BAR | Q28198990 | ||
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 | ||
| The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis | Q28345942 | ||
| Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity | Q28512778 | ||
| Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine | Q28567768 | ||
| MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection | Q28585035 | ||
| Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response | Q28586517 | ||
| Ecological and evolutionary forces shaping microbial diversity in the human intestine | Q29547586 | ||
| Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients | Q29614261 | ||
| The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice | Q29614457 | ||
| Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity | Q29615051 | ||
| Microbiota and SCFA in lean and overweight healthy subjects | Q29615812 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay | Q41187748 | ||
| Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. | Q41546228 | ||
| Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage | Q41839552 | ||
| Hepatocyte-specific hypoxia-inducible factor-1α is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. | Q41988947 | ||
| Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis | Q42925588 | ||
| Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy | Q42950499 | ||
| Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women | Q43141586 | ||
| Role of the gut in the pathophysiology of extrahepatic biliary obstruction | Q43226340 | ||
| Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? | Q43257958 | ||
| Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice | Q43284558 | ||
| Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. | Q43414787 | ||
| Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women | Q43481704 | ||
| Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection | Q44024978 | ||
| Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. | Q44261210 | ||
| Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients | Q44319592 | ||
| Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats | Q44324969 | ||
| Intestinal permeability in liver cirrhosis: relationship with severe septic complications | Q44600299 | ||
| Intestinal permeability is increased in patients with advanced cirrhosis. | Q44627267 | ||
| Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis | Q44880291 | ||
| Large intestine permeability is increased in patients with compensated liver cirrhosis | Q44975067 | ||
| Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants | Q45285259 | ||
| Assessment of the fecal lactobacilli population in patients with hepatitis B virus-related decompensated cirrhosis and hepatitis B cirrhosis treated with liver transplant | Q45362841 | ||
| Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis | Q45569255 | ||
| Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. | Q45973840 | ||
| Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. | Q45980096 | ||
| Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. | Q46038106 | ||
| Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. | Q46085888 | ||
| Serum concentrations of resistin-like molecules beta and gamma are elevated in high-fat-fed and obese db/db mice, with increased production in the intestinal tract and bone marrow | Q46440915 | ||
| TLR4 is the signaling but not the lipopolysaccharide uptake receptor | Q47231518 | ||
| Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. | Q34731373 | ||
| Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. | Q34817375 | ||
| Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice | Q34957338 | ||
| Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. | Q35000892 | ||
| Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice | Q35033766 | ||
| Microbiota and nonalcoholic steatohepatitis | Q35066721 | ||
| Altered profile of human gut microbiome is associated with cirrhosis and its complications | Q35077209 | ||
| Alterations of the human gut microbiome in liver cirrhosis | Q35216354 | ||
| The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice | Q35249092 | ||
| Gut microbiome and nonalcoholic fatty liver diseases | Q35327402 | ||
| Review article: Alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. | Q35586895 | ||
| The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation | Q35661635 | ||
| Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. | Q35693573 | ||
| Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice | Q35825858 | ||
| Linkage of gut microbiome with cognition in hepatic encephalopathy | Q35939338 | ||
| Hepatic TLR4 signaling in obese NAFLD | Q35958528 | ||
| Colonic microbiome is altered in alcoholism. | Q35994007 | ||
| RETRACTED ARTICLE: Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii | Q36028430 | ||
| Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis | Q36168809 | ||
| The gut microbiota and its relationship to diet and obesity: new insights | Q36187676 | ||
| Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice | Q36243894 | ||
| Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation | Q36309525 | ||
| Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure | Q36339602 | ||
| Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice | Q36592306 | ||
| Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. | Q36796803 | ||
| Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. | Q50516235 | ||
| Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. | Q50784627 | ||
| TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. | Q51167343 | ||
| Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. | Q51365041 | ||
| Jejunal microflora in patients with chronic alcohol abuse. | Q51643504 | ||
| The differing effects of acute and chronic alcohol on gastric and intestinal permeability. | Q52512723 | ||
| The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. | Q53643126 | ||
| Intestinal microbiota in patients with nonalcoholic fatty liver disease. | Q54317263 | ||
| Characterization of fecal microbial communities in patients with liver cirrhosis. | Q54372904 | ||
| The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. | Q54584936 | ||
| Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance | Q56742768 | ||
| Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity | Q62066885 | ||
| An outbreak of diphtheria among Swedish alcoholics | Q69471164 | ||
| Effect of rectal infusion of short chain fatty acids in human subjects | Q69714429 | ||
| Small bowel bacterial overgrowth in patients with alcoholic cirrhosis | Q72313593 | ||
| Endotoxin inactivating action of plasma in patients with liver cirrhosis | Q72336284 | ||
| Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia | Q72567619 | ||
| The leaky gut of alcoholism: possible route of entry for toxic compounds | Q72571576 | ||
| Gastrointestinal transit in cirrhotic patients: effect of hepatic encephalopathy and its treatment | Q72694061 | ||
| Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis | Q73584895 | ||
| Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance | Q73769805 | ||
| Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites | Q74367030 | ||
| Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage | Q77957963 | ||
| Etiology of portal hypertension may influence gastrointestinal transit | Q79299175 | ||
| Intestinal microflora in patients with liver cirrhosis | Q81183083 | ||
| Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD) | Q83683089 | ||
| Liver cirrhosis | Q83880575 | ||
| Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation | Q85084971 | ||
| Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet | Q85224285 | ||
| Human gut microbiota in obesity and after gastric bypass | Q29615813 | ||
| NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis | Q29616155 | ||
| Gut Microbiota in Health and Disease | Q29616812 | ||
| Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome | Q29617424 | ||
| Bile salt biotransformations by human intestinal bacteria | Q29622858 | ||
| Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model | Q30486045 | ||
| Ruminococcin A, a new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces | Q31004928 | ||
| Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis | Q31906895 | ||
| FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats | Q33741191 | ||
| Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease | Q33780172 | ||
| Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. | Q33905038 | ||
| Diversity of the autochthonous colonic microbiota | Q33938989 | ||
| Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease | Q33981675 | ||
| Colonic inflammation and secondary bile acids in alcoholic cirrhosis | Q34121950 | ||
| Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach | Q34195561 | ||
| Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. | Q34227211 | ||
| Comparing the effects of acute alcohol consumption in germ-free and conventional mice: the role of the gut microbiota | Q34256050 | ||
| Bacterial colonization leads to the colonic secretion of RELMβ/FIZZ2, a novel goblet cell-specific protein | Q34274465 | ||
| Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides | Q34294058 | ||
| Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis | Q34321742 | ||
| Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease | Q34347996 | ||
| A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis | Q34369987 | ||
| Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats | Q34386625 | ||
| Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity | Q34409186 | ||
| Diphtheria among alcoholic urban adults. A decade of experience in Seattle | Q34414643 | ||
| Recent advances in the development of farnesoid X receptor agonists | Q34464043 | ||
| Gut microbiota-related complications in cirrhosis | Q34499061 | ||
| Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia | Q34527838 | ||
| Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment | Q34551121 | ||
| Modulation of the fecal bile acid profile by gut microbiota in cirrhosis | Q34554908 | ||
| Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis | Q34560068 | ||
| Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits | Q34596030 | ||
| Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study | Q34702127 | ||
| Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis | Q34713484 | ||
| Alterations in intestinal microbial flora and human disease | Q34718894 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 759-91 | |
| P577 | publication date | 2015-10-28 | |
| P1433 | published in | Microorganisms | Q27725360 |
| P1476 | title | Gut Microbiota and Host Reaction in Liver Diseases | |
| P478 | volume | 3 |
| Q90009862 | Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications |
| Q55322856 | Changes of Intestinal Functions in Liver Cirrhosis. |
| Q91783628 | Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis |
| Q46222234 | Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation |
| Q90176538 | Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems |
| Q41706834 | Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step |
| Q38670242 | Gut microbiota changes and chronic hepatitis C virus infection. |
| Q50128474 | Improve gut microbiome: a new horizon of cancer therapy |
| Q55252106 | Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? |
| Q42372550 | Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts |
| Q38750137 | Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine |
| Q59353836 | The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection |
Search more.